HC Wainwright & Co. Reiterates Buy on Opus Genetics, Maintains $8 Price Target

Opus Genetics, Inc.

Opus Genetics, Inc.

IRD

0.00

HC Wainwright & Co. analyst Matthew Caufield reiterates Opus Genetics (NASDAQ: IRD) with a Buy and maintains $8 price target.